DisCoVeRy trial of Verklury concluded there was no clinical benefit in hospitalised patients with COVID 19 – Gilead Sciences (in 2021)

https://medicalupdateonline.com/2021/09/discovery-trial-of-verklury-concluded-there-was-no-clinical-benefit-in-hospitalised-patients-with-covid-19-gilead-sciences/

A study conducted in Europe of Gilead’s Verklury (remdesivir) concluded that the antiviral provided no clinical benefit in hospitalized patients with COVID-19 compared to existing treatments . The phase III open-label DisCoVeRy trial included patients admitted to hospital with laboratory-confirmed SARS-CoV-2 and if they had evidence of pneumonia or required oxygen. Participants were randomized to standard of care alone or in combination with remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, or hydroxychloroquine.Clinical status at day 15 measured by the WHO seven-point ordinal scale.